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ABSTRACT
Ultraconserved regions (UCRs) have been shown to originate non-coding RNA 
transcripts (T-UCRs) that have different expression profiles and play functional roles 
in the pathophysiology of multiple cancers. The relevance of these functions to the 
pathogenesis of bladder cancer (BlCa) is speculative. To elucidate this relevance, 
we first used genome-wide profiling to evaluate the expression of T-UCRs in BlCa 
tissues. Analysis of two datasets comprising normal bladder tissues and BlCa 
specimens with a custom T-UCR microarray identified ultraconserved RNA (uc.) 8+ as 
the most upregulated T-UCR in BlCa tissues, although its expression was lower than 
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in pericancerous bladder tissues. These results were confirmed on BlCa tissues by  
real-time PCR and by in situ hybridization. Although uc.8+ is located within intron 1 
of CASZ1, a zinc-finger transcription factor, the transcribed non-coding RNA encoding 
uc.8+ is expressed independently of CASZ1. In vitro experiments evaluating the effects 
of uc.8+ silencing, showed significantly decreased capacities for cancer cell invasion, 
migration, and proliferation. From this, we proposed and validated a model of interaction 
in which uc.8+ shuttles from the nucleus to the cytoplasm of BlCa cells, interacts 
with microRNA (miR)-596, and cooperates in the promotion and development of BlCa. 
Using computational analysis, we investigated the miR-binding domain accessibility, 
as determined by base-pairing interactions within the uc.8+ predicted secondary 
structure, RNA binding affinity, and RNA species abundance in bladder tissues and 
showed that uc.8+ is a natural decoy for miR-596. Thus uc.8+ upregulation results in 
increased expression of MMP9, increasing the invasive potential of BlCa cells. These 
interactions between evolutionarily conserved regions of DNA suggest that natural 
selection has preserved this potentially regulatory layer that uses RNA to modulate miR 
levels, opening up the possibility for development of useful markers for early diagnosis 
and prognosis as well as for development of new RNA-based cancer therapies.
INTRODUCTION
Ultraconserved regions (UCRs) are sequences of the 
human genome located within intragenic and intergenic 
regions that are absolutely conserved (100% identity 
with no insertions or deletions) among orthologous 
regions of the human, rat, and mouse genomes [1]. 
Transcribed ultraconserved regions (T-UCRs) constitute 
a novel category of long non-coding RNAs. T-UCRs are 
often contained in RNA sequences that extend beyond 
the conserved regions described by Bejerano et al [1], 
and their functional role in the biology of cancer and 
development remains to be determined. Following our 
initial report that profiled T-UCRs for B-cell chronic 
lymphocytic leukemia [2], other groups profiled T-UCRs 
and suggested that these long non-coding RNAs could 
contribute to the development of pediatric tumors, 
neuroblastoma, and prostate cancer [3]. Researchers have 
described a role for ultraconserved RNAs (uc).73+A and 
uc.338+ as oncogenes in colorectal cancer samples [4], 
whereas other groups identified uc.388+ as an oncogene in 
hepatocellular carcinoma tissues [5]. Recently, researchers 
found uc.283+ to be highly specific for pluripotent stem 
cells and highly expressed in cases of glioma, one of the 
most untreatable cancers [6].
While microRNAs (miR) and other types of 
non-coding RNAs, such as metastasis-associated lung 
adenocarcinoma transcript 1 (MALAT1), imprinted 
maternally expressed transcript (H19), and long intergenic 
noncoding RNA Up-regulated in bladder cancer 1 (linc-
UBC1), greatly contribute to the biological function of 
bladder cancer (BlCa) and are being increasingly explored 
to improve the clinical care of patients, the biological 
importance of these UCRs in the pathogenesis of BlCa has 
not yet been investigated, and their function is currently 
unknown. These elements are more highly conserved than 
protein coding regions, suggesting that these segments 
have important, if not vital, biological functions.
 We present here a comprehensive genomic 
examination of the transcriptional status of UCRs in a 
large panel of human BlCa samples. T-UCRs exert their 
biological function by sequence complementarity to other 
RNAs species. We proposed and validated a model in 
which uc.8+ acts as an efficient decoy for miR-596 and 
plays an important regulatory role in BlCa tumorigenesis.
RESULTS
Identification of differentially expressed T-UCRs 
in BlCa and normal bladder tissues
To identify the differential expression of T-UCRs 
in BlCa and normal bladder epithelium (NBE) tissues, 
we evaluated expression data on 962 sense and antisense 
transcripts of 481 known UCRs using a custom microarray 
previously used to examine ultraconserved genome 
expression profiles in patients with leukemia, colon 
cancer, or hepatocellular cancer [2, 5, 7].
We first compared the ultraconserved genome 
profiles for 24 BlCa patient samples (1_BlCa) and 17 
NBE samples (1_NBE; clinical characteristics in Table 1 , 
dataset 1). Analysis of microarrays for two-class unpaired 
data comparison [8] identified 293 T-UCRs (~60% of 
all T-UCRs analyzed) that were differentially expressed 
at a statistically significant level (P<0.05, q<0.025) 
in 1_BlCa and 1_NBE (Supplementary Table S1, top-
ranked T-UCRs). Of these, the expression of 75 of them 
increased by 1.1 to 6.7 fold in the BlCa samples; whereas 
the expression of 218 of them decreased by 0.9 to 0.2 fold 
in BlCa tissues. Compared with the NBE samples, uc.8+ 
expression increased the most (6.6 fold; P = 0.001), and 
uc.217+A expression decreased the most (5.0 fold) in 
BlCa samples (Figure 1A).
Because researchers previously showed that 
histological samples of apparently NBE obtained from 
BlCa patients exhibited genetic alterations [9], we 
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compared the ultraconserved genome profiles of BlCa 
samples collected from three patients and matched 
pericancerous BlCa (PBlCa) tissues (urothelium 
surrounding the tumors) obtained from the same patients 
(clinical characteristics are shown in Table 1 , dataset 
2). We identified 141 T-UCRs that were differentially 
expressed (Supplementary Table S2). Compared with the 
PBlCa samples, in BlCa samples, the expression of six of 
these T-UCRs increased by 1.3 to 1.9 fold, whereas the 
expression of 135 decreased by 0.8 to 0.2 fold. uc.195+ 
was the most upregulated and uc.8+ was the most 
downregulated in BlCa compared with PBlCa (Figure 1B). 
We merged the data of differentially expressed T-UCRs 
obtained from these two comparisons (1_BlCa/1_NBE 
and 2_BlCa/2_PBlCa) and identified 50 T-UCRs for which 
the change in expression was concordant (Figure 1C).
For these T-UCRs, we correlated the magnitude of 
the fold change in the two comparisons. We observed good 
overall correspondence in the fold increase of T-UCR 
expression (r=-0.4358, P<0.001). Few outliers drove 
this trend, with the most extreme being uc.8+ (6.6 fold 
increase when comparing BlCa with NBE versus 0.3 fold 
decrease when comparing BlCa with PBlCa).
To understand the regulation of T-UCRs during 
BlCa progression, we compared T-UCR expression in 
BlCa, PBlCa, and NBE tissue samples using data from the 
microarray. We found that some T-UCRs were differently 
expressed in these three tissue types (Supplementary 
Figure S1A and S1B). Particularly, expression of uc.8+, 
uc.78+, uc.249+, uc.282+, and uc.339+ was markedly 
higher in PBlCa than in NBE but was markedly lower 
in BlCa than in PBlCa tissues (Supplementary Figure 
S1A). Nevertheless, the expression of these T-UCRs 
in PBlCa tissues seemed to be higher than in NBE, and 
this difference was statistically significant only for uc.8+ 
and uc.339+ (P<0.001). Nevertheless, a large population 
may achieve statistical significance for the difference in 
expression of the other deregulated T-UCRs shown in 
Supplementary Figure S1A and S1B.
uc.8+ was the most upregulated ultraconserved 
element in PBlCa tissue samples (Figure 1D) when 
compared with corresponding BlCa tissue samples (3_
BlCa and 3_PBlCa) obtained from 18 patients (clinical 
characteristics are shown in Table 1 , dataset 3). These 
findings suggest that BlCa and PBlCa tissues have 
different UCR transcription patterns.
Table 1: Clinical characteristics of patients with bladder cancer (BlCa)*
Features Dataset 1 Dataset 2 Dataset 3 Dataset 4 Dataset 5
1_BlCa 
(N=24)
1_NBE 
(N=17)
2_BlCa 
(N=3)
2_PBlCa 
(N=3)
3_BlCa 
(N=18)
3_PBlCa 
(N=18)
1_BlCa 
(N=40)
1_NBE 
(N=16)
1_BlCa 
(N=18)
Age 
(mean±SD)
64.5
±13.8
61.9
±7.1
60.6
±8.0
60.6
±8.0
63.0
±15.7
63.0
±15.7
68.9
±10.3
65.6
±3.4
72.1
±12.4
Sex
(male/
female)
19/5 17/0 3/0 3/0 16/2 16/2 27/13 16/0 12/6
Clinical 
stage
Ta–T0 12 / / / 5 / 9 / 3
T1 3 / 1 / 4 / 10 / 3
T2 3 / 1 / 4 / 7 / 3
T3–T4 6 / 1 / 5 / 14 / 9
Pathological 
grade
G1 4 / / / 6 / 12 / 6
G2 8 / 2 / 4 / 8 / 6
G3 12 / 1 / 8 / 20 / 6
*The median follow-up duration for these patients was 27.82 months.
All patients were classified according to the 1997 UICC TNM classification for the stage and OMS 2004 for the grade.
Abbreviations: SD, standard deviation; NBE, normal bladder epithelium; PBlCa, pericancerous BlCa; ISH, in situ 
hybridization.
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Validation of differentially expressed T-UCRs
To validate the results obtained by microarray 
analysis, we assayed the expression of four ultraconserved 
RNAs (uc.8+, uc.195+, uc.339+, and uc.217+A), by 
quantitative real-time polymerase chain reaction (qRT-PCR) 
in a subset of 22 patients and 10 normal controls randomly 
selected from dataset 4 (clinical characteristics are shown 
in Table 1). The results showed an increase of 6.5 fold for 
uc.8+, an increase of 2.45 fold for uc.339+, a decrease of 
0.105 fold for uc.195+, and a decrease of 0.25 fold for 
uc.217+A in BlCa tissues compared with NBE (Figure 
1E). These results are consistent with the trend shown by 
microarray analysis results and indicate the primary role 
that uc.8+ may have in BlCa onset and progression.
Genomic features of the investigated T-UCRs
We investigated the genomic properties of the 
293 T-UCRs identified by the microarray analysis and 
determined their transcript localization. Since a gene 
may have multiple slightly different transcripts, the same 
T-UCR can have multiple localizations, i.e., the T-UCR 
might be exonic in one transcript and intronic in another. 
We denoted this possibility as multiple T-UCRs mapping 
to different regions in different transcripts to distinguish it 
Figure 1: Transcribed ultraconserved region (T-UCR) expression in human bladder cancer (BlCa) tissues. A. Bar plot 
of the expression of a subset of the investigated T-UCRs (48 of 293) with expression increases greater than 2 fold and expression decreases 
lower than -2.3 fold in BlCa and normal bladder epithelium (NBE) tissues. B. Bar plot of the expression of a subset of the investigated 
T-UCRs (48 of 141) with expression increases greater than 1 fold and expression decreases lower than -1.66 fold in BlCa and pericancerous 
BlCa (PBlCa) tissues.C. Comparison of the fold change in expression of 50 T-UCRs for which two different controls (NBE and PBlCa 
tissues) were used. The outlying ultraconserved RNA (uc).8+ is shown in red. D. RNA was extracted from 18 BlCa and adjacent PBlCa 
tissues. Evaluation of uc.8+ expression was assessed by quantitative real-time polymerase chain reaction (qRT-PCR). The expression of 
uc.8+ is higher in PBlCa than in BlCa tissues. ***P<0.001. E. Box plot of the fold change in uc.8+, uc.195+, uc.339+, and uc.217+A 
expression in BlCa and NBE samples according to qRT-PCR analysis of at least three biological repeats (subset of 22 BlCa patients and 
10 NBE; Table 1, dataset 4). The bold lines inside the boxes in panels D and E represent the medians. The boxes represent the first (Q1) 
and the third (Q3) quartiles, and the two whiskers represent the minimum and the maximum values, except for outliers. Circles represent 
outliers, i.e., values lower than Q1-1.5 (Q3-Q1) or higher than Q3+1.5 (Q3-Q1). P values were obtained using the Mann-Whitney U test. 
***P<0.001. F. T-UCR classification with respect to the transcripts as single, multiple, or intergenic is depicted for all T-UCRs and for the 
group of T-UCRs that are deregulated in BlCa tissues. Selective enrichment of a specific group of T-UCRs was not observed in BlCa tissues. 
Source data for this figure are available online. Abbreviations: ucRNA, ultraconserved RNA; T-UCR, transcribed ultraconserved region; 
qRT-PCR, quantitative real-time polymerase chain reaction.
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from cases in which the T-UCR maps to a single transcript 
or to the same position in all transcripts (Supplementary 
Figure S2A and S2B and Supplementary Table S3). Of the 
293 T-UCRs considered in this study, we found that most 
were single (62%), some were intergenic (26%), and a few 
had multiple transcripts (12%). uc.285+ is an example of 
T-UCR that maps to multiple transcripts of CCAR1 gene 
(Figure S2B). None of these categories was selectively 
enriched in BlCa tissues, and the proportion was similar 
to those of all T-UCRs (Figure 1F).
Increased uc.8+ expression in BlCa tissues
To gain insight into the in vivo role of uc.8+, we 
studied its expression profile in BlCa tissues by in situ 
hybridization experiments (Figure 2A, 2B, and 2C). We 
used a digoxigenin-labeled RNA antisense uc.8+ probe 
and analyzed 18 BlCa samples (Table 1, dataset 5). 
We detected uc.8+ expression in most of the samples 
(15/18): in seven out of nine high-grade tumors and in 
eight out of nine low-grade tumors. Positive spots were 
observed mainly in the nucleus in both adjacent normal 
tissues and high-grade BlCa, whereas in low-grade BlCa 
spot signals were mainly delocalized in the cytoplasm 
(Figure 2A’, 2B’, and 2C’). Importantly, the shuttling 
of uc.8+ from the nucleus to the cytoplasm could 
suggest the interaction of uc.8+ with other cytoplasmic 
molecules.
Next, we looked at uc.8+ expression in 40 BlCa 
patients (Table 1, dataset 4). We confirmed that the 
expression of uc.8+ is upregulated in BlCa, but uc.8+ 
expression tended to be inversely related to BlCa grade 
(Figure 2D), suggesting an association between loss of 
tumor differentiation and low uc.8+ expression. We found 
the same results when we considered uc.8+ expression and 
BlCa stage (Figure 2E), suggesting an early alteration of 
uc.8+ expression in BlCa development.
Genomic features and transcriptional regulation 
of uc.8+
To evaluate the potential interrelationship between 
CASZ1 and uc.8+ transcription, we first examined the 
expression of CASZ1 by qRT-PCR for a subset of 19 
patients with BlCa at different stages and 11 NBE controls 
randomly selected from dataset 4 (Table 1). CASZ1, 
which maps to 1p36.22, is a recently described zinc-finger 
transcription factor. CASZ1 acts as a tumor suppressor 
gene, and researchers have shown that CASZ1 is 
downregulated in high-risk phenotypes of neuroblastoma 
[10]. The primers used spanned a genomic region in 
CASZ1 exon 6–8, which was distant from the uc.8+ region 
Figure 2: Ultraconserved RNA (uc). 8+ expression in human bladder cancer (BlCa) tissues. Representative images show the 
expression of uc.8+ by in situ hybridization in A. normal bladder epithelium (NBE), B. low-grade BlCa tissues, and C. high-grade BlCa 
tissues. A’, B’, and C’ represent enlargement of specific areas. D. uc.8+ expression evaluated by qRT-PCR was stratified according to grade 
of BlCa (n=40; Table 1, dataset 4). E. uc.8+ expression evaluated by qRT-PCR in BlCa tissues (n=40) was stratified according to stage. The 
bold lines inside the boxes in panels D and E represent the medians. The boxes represent the first (Q1) and the third (Q3) quartiles, and the 
two whiskers represent the minimum and the maximum values, except for outliers. Circles represent outliers, i.e., values lower than Q1-1.5 
(Q3-Q1) or higher than Q3+1.5 (Q3-Q1). P values were obtained using the Mann-Whitney U test. ***P<0.001.
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(Figure 3A). The results indicated a positive correlation 
between the expression of the host gene CASZ1 and uc.8+ 
(r=0.83, P<0.001; Figure 3B). The CASZ1/uc.8+ ratio in 
NBE controls highly favored CASZ1 expression, whereas 
in cancer patients, the ratio shifted in favor of uc.8+ 
expression in the different stages of BlCa (Supplementary 
Figure S3).
We next evaluated the uc.8+/CASZ1 expression ratio 
in BlCa cell line J82, which had higher expression of uc.8+ 
than BlCa cell line RT112 (Supplementary Figure S4). We 
compared uc.8+ knockdown in J82 cells transfected with 
three different small interfering RNAs (siRNAs) against 
uc.8+ and a siRNA control (Supplementary Figure S5A) 
and found that siRNA-3 anti-uc.8+, at a final concentration 
of 200 nM, was the most effective.
The oligonucleotides used to silence the expression 
of uc.8+ had no effect on the expression of the host gene 
CASZ1 (Figure 3C). Furthermore, uc.8+ expression 
was unchanged in siRNA-2 anti-CASZ1–transfected 
J82 cells (Figure 3D), despite a 78% of reduction in 
CASZ1 expression (Supplementary Figure S5B). These 
observations confirmed that uc.8+ was not expressed as 
part of CASZ1 gene.
In humans, we observed that uc.8+ is located within 
intron 1 of CASZ1 near six other T-UCRs: uc.2+ and uc.3+ 
are located within intron 4, uc.4+ is located within intron 
3, uc.5+ and uc.6+ are located within intron 2, and uc.7+ 
is located within intron 1 of the main transcript identified 
as CASZ1 (Figure 4A and 4B). The six T-UCRs localized 
in CASZ1 exhibited very low levels in BlCa compared 
with NBE samples (Figure 4C). Accordingly, we observed 
a negative correlation between the expression of all the 
T-UCRs contained in CASZ1 and CASZ1 (Figure 4D) 
in BlCa patients, supporting a role for uc.8+ in BlCa 
Figure 3: Independent regulation of ultraconserved RNA (uc). 8+ and CASZ1 in bladder cancer (BlCa) tissues. A. Schematic 
representation of the intronic localization of uc.8+ within CASZ1. CASZ1 exons are indicated by black boxes. The locations of the uc.8+ 
forward (F) and reverse (R) primers used for qRT-PCR and the probe used for in situ hybridization are shown. Of the siRNAs targeting 
CASZ1, siRNA-1 is located at the 5′ untranslated region (UTR), siRNA-2 is located in exon 6, and siRNA-3 is located at the 3′ UTR. B. 
RNA levels of CASZ1 and uc.8+ were determined by qRT-PCR in BlCa (n=19, black dots) and control normal bladder epithelium (NBE) 
samples (n=11, empty circles). Results are presented as means ± standard deviation (SD). Spearman correlation coefficient and P values 
are indicated. C. CASZ1 expression after silencing of uc.8+. The expression of CASZ1 was not affected in J82 cells transfected with three 
different siRNAs anti-uc.8+ or siRNA control. D. J82 cells were transfected with siRNA anti-CASZ1 or siRNA control. The CASZ1 level 
was determined by qRT-PCR. uc.8+ expression was not affected by any of the siRNAs anti-CASZ1 used. Data are expressed as the mean 
± SD of triplicate values.
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progression. These findings exclude the basic hypothesis 
that uc.8+ works as an antisense controller of CASZ1 and 
indicate that the expression of uc.8+ is independent of the 
expression of CASZ1.
Identification of the full-length transcript 
encoding uc.8+
We further characterized the uc.8+ transcript to 
understand its relevance observed in BlCa. We cloned the 
Figure 4: Correlation of transcribed ultraconserved regions (T-UCRs) with the host gene CASZ1 in bladder cancer 
(BlCa). A. Representation of the genomic localization of CASZ1 with respect to 1p36.22 (red) obtained using the UCSC Genome Browser 
(University of California Santa Cruz). B. Representation of the seven T-UCRs in CASZ1 according to their genomic locations with respect 
to protein-coding genes (CASZ1 defined using the RefSeq database). C. The expression levels for all T-UCRs located in CASZ1 were 
measured using qRT-PCR. RNA was extracted from BlCa tissues obtained from 24 patients (dark gray) and 17 normal bladder epithelium 
(NBE) samples (gray) (Table 1, Dataset 1). The bold lines inside the boxes represent the medians. The boxes represent the first (Q1) and the 
third (Q3) quartiles, and the two whiskers represent the minimum and the maximum values, except for outliers. Circles represent outliers, 
i.e., values lower than Q1-1.5 (Q3-Q1) or higher than Q3+1.5 (Q3-Q1). D. Representative negative correlation of CASZ1 and T-UCR 
(uc.2+–uc.7+) expression in patients with BlCa (n=14). qRT-PCR analysis results of CASZ1 expression (abscissa) versus T-UCR expression 
are shown.
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full-length uc.8+ transcript using rapid amplification of 
cDNA ends (RACE) and designated the DNA sequence as 
TUC8. The genomic location of TUC8 is shown in Figure 
5A. J82 RNA was retrotranscribed with the SMARTScribe 
Reverse Transcriptase to generate a complete cDNA copy of 
the original RNA with an additional SMARTer sequence at 
the end that served as a template for the reverse transcription. 
To study TUC8, we used intronic primers that would not 
recognize the CASZ1 coding sequence (Figure 5A). No 
products were produced with the antisense intronic primer, 
suggesting that TUC8 is not encoded in antisense. PCR 
with the intronic sense primer produced a single defined 
band of ~1269 nt that was further sequenced, leading to 
the characterization of the 5′ end of TUC8 (Supplementary 
Figure S6A). As shown in Figure 5B and Supplementary 
Figure S6B, 3′ RACE studies identified 950 nt at the 3′ end 
downstream from the uc.8+ sequence identified by Bejerano 
et al [1]. The TUC8 gene has a total of 2435 bases, including 
the 216-nt ultraconserved (uc.8+) sequence from position 
-950 to position +1269 upstream from the 3′-untranslated 
region (Figure 5C).
We used the Open Reading Frame Finder in the 
Sequence Manipulation Suite [11] to scan TUC8 for open 
reading frames at least three codons long that could begin 
with any codon and be located in any possible frame on 
both direct and reverse strands according to the standard 
genetic code. We identified eight possible open reading 
frames starting with an ATG codon, ending with a stop 
codon, and comprising 3 to 34 codons (Supplementary 
Table S4). We scanned the full-length uc.8+ transcript 
sequence using the PROSITE protein database [12], 
excluded motifs with a high probability of occurrence, 
and found no protein domains or relevant functional sites 
within uc.8+ sequence. We concluded that uc.8+ is part 
of TUC8, which is transcribed independently on CASZ1.
Uc.8+ and BlCa cell proliferation, migration, and 
invasion
To determine the role of endogenous uc.8+ 
expression in BlCa, we examined the effect of uc.8+ 
silencing on J82 cell proliferation, migration, and 
Figure 5: Features of intronic location of ultraconserved RNA (uc). 8+ in CASZ1. A. Schematic representation of the transcript 
including uc.8+ with respect to CASZ1. J82 RNA was retrotranscribed by using the SMARTer Rapid Amplification of cDNA Ends (RACE) 
cDNA Amplification kit (Clontech). Primers used for the 5′ RACE were as follows: Universal Primer Mix (UPM) that recognized the 
SMARTer oligonucleotide added at the 5′ end, gene specific primers 1 (GSP1) that recognized the sense transcript, and GSP2 primers that 
recognized the antisense transcript. The arrows represent the direction of amplification from the gene-specific primers that successfully 
amplified the unknown regions of the TUC8 gene. B. 5′- and 3′-RACE polymerase chain reaction (PCR) performed to amplify the uc.8+ 
cDNA. C. Sequence of the complete uc.8+ transcript (2435 bases) as determined using RACE. The yellow sequence was reported by 
Bejerano et al, 2004 [1].
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invasion. As shown in Figure 6A, after 24 hours, 
growth was greatly reduced, by 55.46% ± 1.30% (mean 
± standard deviation [SD]) in siRNA-3 anti-uc.8+–
transfected cells and by 26.84% ± 1.10% (mean ± SD) 
in siRNA-2 anti-uc.8+–transfected cells, when compared 
with control siRNA–transfected cells. We next used 
cytofluorometry to assess the effects of uc.8+ silencing 
on J82 cell-cycle distribution. Compared with the control, 
siRNA-3 anti-uc.8+–transfected samples had 45% fewer 
cells in S phase (P<0.05) and 7% fewer cells in G2/M 
phase (Figure 6B).
We performed an in vitro wound-healing assay 
to measure cell migration, 36 h after silencing uc.8+ 
(Figure 6C). Imaging of cell migration revealed that 
uc.8+ silencing impaired the motility of J82 cells in vitro 
by about 40% when compared with control siRNA–
transfected cells (Figure 6D). As shown in Figure 6E and 
6F, uc.8+ silencing markedly inhibited cellular invasion 
when compared with corresponding control cells in a 
transwell invasion assay. Taken together, these results 
suggest that uc.8+ silencing suppressed the ability of BlCa 
cells to proliferate, migrate, and invade in vitro.
Figure 6: Effect of ultraconserved RNA (uc). 8+ silencing on bladder cancer (BlCa) cell proliferation, migration, and invasion. 
A. J82 cells were transfected with siRNA anti-uc.8+ or siRNA control and were seeded in 96-well plates. Cell proliferation was determined 
at the indicated time points. The number of cells per well was measured by the absorbance at 595 nm. The results show data from at 
least three independent experiments. Cell growth after transfection with siRNA-3 anti-uc.8+ was not significantly different from that 
of cells transfected with siRNA-2 anti-uc.8+. P values were obtained using the Student t test for independent samples. *P<0.05. B. J82 
cells were transfected with siRNA-3 anti-uc.8+ or siRNA control for 72 h, and analysis of cell-cycle distribution was performed by flow 
cytofluorometry. Bars represent the means and standard deviation (SD) of three experiments. P values were obtained using the Student t 
test for independent samples. *P<0.05. C. J82 cells were transfected with siRNA-3 anti-uc.8+ or siRNA control. After 24 h, a single scratch 
was made in the urothelial monolayer. Cell migration was quantified by measuring the distance between the invading front of the cells in 
three randomly selected microscopic fields (magnification 20x) for each condition and time point. The degree of motility is expressed as the 
percentage of wound closure compared with the zero time point. Data are representative of three experiments and are expressed as means ± 
SD. P values were obtained using the Student t test for independent samples. **P<0.01 and ***P<0.001. D. Representative views of wound 
healing assay was captured and recorded at 0 and 36 h demonstrating reduced migration of J82 cells after uc.8+ silencing. The scale bar 
in the image is 300 µm. Magnification, 100× (panel I–VI). E. The number of invasive J82 cells in mock, scrambled siRNA, and siRNA-3 
anti-uc.8+ groups, which were significantly higher than those in the siRNA-3 anti-uc.8+–transfected group. Data are representative of three 
experiments and are expressed as means ± SD. P values were obtained using the Student t test for independent samples. **P<0.01 and 
***P<0.001. F. Representative microscopic images (magnification, 20×) with crystal violet staining of migrated J82 cells. Mock, scrambled 
siRNA, and siRNA-3 anti-uc.8+ transfected cells are shown (panel I to III).
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Correlation between uc.8+ and miR-596 
expression in BlCa
Since many long non-coding RNAs function as 
transcription regulators in RNA-RNA and RNA-DNA 
interactions via simple one-to-one base pairing [2, 3], we 
hypothesized that T-UCRs may exert their function by 
regulating other RNAs. To explore this possible function 
of UCR-encoded transcripts, we used the RNAhybrid 
target prediction software program [13] to identify putative 
miR target sites in all T-UCRs described by Bejerano et al 
[1]. By using highly stringent conditions to predict miR 
binding sites, we identified only two miR-binding sites—
for miR-596 (Supplementary Figure S7A) and miR-381-
3p (Supplementary Figure S7B)—on the uc.8+ sequence.
We focused on the uc.8+::miR-596 interaction for 
two reasons. First, the RNA duplex uc.8+::miR-596 has 
a high probability to form in vivo with a low minimum 
free energy (MFE) value of -33.5 kcal/mol and a 
statistically significant P value of 0.001926. With this 
small P value, it is unlikely that the MFE is the result of 
a random complementarity between miR and the target, 
and biological relevance can be assumed. Second, in a 
comparison of the predicted uc.8+ secondary structure 
(Supplementary Figure S7C and S7D) with the entire 
RNA sequence of 2435 bases transcribed in vitro (RACE 
analysis, Figure 5C), we observed that the uc.8+ sequence 
reported by Bejerano et al [1] folds in the same manner as 
the full-length transcript we found. The three-dimensional 
structure of uc.8+ remains sufficiently accessible, with a 
MFE value of only -3.90 kcal/mol, to bind to miR-596 
(Supplementary Figure S7E). With a fairly good MFE 
value of -27.1 kcal/mol and a P value of 0.025596, the 
predicted RNA duplex uc.8+::miR-381-3p also has a high 
probability of forming in vivo. We found that the binding 
site for miR-596 on uc.8+ is localized in a region that is 
structurally available to binding, showing 18 out of the 23 
bases involved in the interaction with miR-596. However, 
the secondary structure of uc.8+ suggests that it is more 
likely to form an RNA duplex with miR-596.
To determine the biological significance of the 
predicted uc.8+::miR-596 RNA duplex, we used qRT-
PCR to investigate the correlation between uc.8+ and 
miR-596 expression in a subset of 20 BlCa tissue samples 
(Table 1, dataset 4). The BlCa samples had consistently 
lower miR-596 expression than the control; miR-596 
expression inversely and significantly correlated with 
uc.8+ expression (r=-0.94, P<0.001; Figure 7A).
Identification of uc.8+::miR-596 interaction 
using a fishing/competition approach
We used a fishing/competition approach to directly 
validate the interaction between uc.8+ and miR-596. We 
identified a single-strand region of uc.8+ to design an 
antisense complementary probe to capture endogenously 
expressed uc.8+. We used the RNAfold web server 
(version 2.1.5, Vienna RNA Package) to identify the uc.8+ 
secondary structure (216 bp) and sequences in a single 
strand, which formed loops even after miR-596 binding.
A key to our approach was to use biotinylated 
peptide nucleic acid (PNA) oligomers as a probe for 
fishing for uc.8+. The PNA sequence is complementary 
to the predicted single-strand region of uc.8+ 
(highlighted in blue in Supplementary Figure S7C and 
S7D). We chose the PNA oligomer instead of standard 
synthetic oligonucleotides because of its ability to bind 
complementary RNAs with high affinity and specificity 
independently from the ionic strength of the buffer (see 
Materials and Methods). We designed and tested probes 
PNA1 and PNA2, which are perfectly complementary 
to the uc.8+ sequence. We verified the ability of these 
PNA probes to capture uc.8+ in a sequence-specific 
manner by incubating the probes with total RNA extracts, 
immobilizing the endogenous hybrids PNA::uc.8+ on 
streptavidin beads, and amplifying uc.8+ using qRT-PCR. 
We found that PNA1 captured a large amount of uc.8+, so 
we chose PNA1 for the fishing approach (Supplementary 
Table S5, Supplementary Figure S7C and S7E [light blue], 
and Supplementary Figure S8). We used a scrambled 
PNA probe with no sequence homology with any human 
RNAs (input reads) as a negative control. Finally, we 
used streptavidin beads to isolate target RNAs (uc.8+ and 
its interactors) from J82 cells. RT-PCR analysis results 
for candidate miR demonstrated a marked enrichment 
of miR-596 compared with the input reads (Figure 7B). 
Furthermore, uc.8+ knockdown resulted in a concomitant 
increase in miR-596 expression by about four fold in 
J82 cells (P<0.001; Figure 7C), supporting a biological 
correlation between the two molecules.
To further demonstrate that miR-596 binds to 
uc.8+, we set up a competition assay. We transfected 
J82 cells with a PNA mimic of miR-596 (PNA-596; 
final concentration, 200 nM; Figure 7D). In contrast to 
the partial complementarity observed with miR target 
interactions, the PNA-596 was designed to be perfectly 
complementary to the uc.8+ sequence. PNA-596 competes 
only with endogenous miR-596 for binding to uc.8+ and 
efficiently displaces miR-596 in a sequence-specific 
manner (Figure 7E and 7F). After 48 h, levels of miR-
596 were analyzed by RT-PCR. The complex formed 
by PNA-596/DNA (oligonucleotide primers used in the 
PCR) blocked the formation of a PCR product [14] and 
allowed the selective amplification of endogenous miR-
596. Expression of miR-596 was significantly increased, 
by 77% (P<0.001), in PNA-596–transfected J82 cells 
compared with the control (Figure 7D), confirming the 
binding of miR-596 to uc.8+.
Cellular localization of uc.8+ by light-up 
PNA probes
The interaction between uc.8+ and miR-596 
suggests that T-UCRs are located in the cytoplasm 
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because miR interaction occurs preferentially in this 
subcellular compartment. To confirm our previous in 
situ hybridization finding, which indicated that uc.8+ 
is preferentially located in the cytoplasm of BlCa cells, 
we employed the PNA1 sequence (PNA-uc.8+) further 
modified by a polyarginine at the C-terminus and by the 
fluorescent probe thiazole orange (TO) at the N-terminus. 
The polyarginine sequence at a final concentration of 4 
μM has been demonstrated to efficiently carry PNAs 
into the cytoplasm of many cells [15]. TO is defined as a 
light-up probe because its fluorescence strongly increases 
after hybridization of the TO-modified oligomer to a 
complementary RNA sequence. As shown in Figure 8A, 
only a light background was evident in the cytoplasm of 
J82 cells transfected with the PNA scramble sequence, 
whereas cells transfected with PNA-uc.8+ showed 
increased fluorescence. This increased fluorescence 
indicates the presence of uc.8+ in the cytoplasm and 
suggests that the uc.8+::miR-596 complex is also located 
in the cytoplasm.
Effect of uc.8+ silencing on BlCa progression
On the basis of our findings of the phenotypic 
consequences of uc.8+ downregulation, we investigated 
the effect of uc.8+::miR-596 complex formation on the 
target of miR-596 and on BlCa formation. Because Endo 
et al [16] demonstrated that matrix metallopeptidase 9 
(MMP9) is modulated by miR-596 in oral squamous cell 
carcinoma cell lines, we hypothesized that uc.8+ may 
regulate the expression of MMP9, a mesenchymal marker 
that is overexpressed in muscle-invasive BlCa cells, via 
binding to miR-596. We observed an inverse correlation 
between the expression of miR-596 and that of its putative 
target MMP9 in BlCa tissues (Figure 8B), suggesting 
that uc.8+ acts as a decoy for miR-596, preventing the 
binding to the miR targets. To confirm these observations, 
we evaluated the effect of uc.8+ silencing on MMP9 
expression and observed a decrease in MMP9 expression 
of about 50% compared with the control (P<0.01) (Figure 
8C). These results suggest that miR-596 has a tumor-
suppressive effect in BlCa and that uc.8+ promotes BlCa.
Figure 7: Ultraconserved RNA (uc). 8+ and microRNA (miR)-596 interaction and target regulation in bladder cancer (BlCa) 
cells. A. Representative positive correlation between the expression of uc.8+ and that of miR-596 in BlCa samples from 20 patients (Table 
1, dataset 4) measured using qRT-PCR. Correlation was computed using the Spearman correlation coefficient. B. Expression of miR-596 
in J82 cell extracts after retrieval of endogenous uc.8+ with a peptide nucleic acid (PNA)/uc.8+ probe. Data are expressed as the means 
± standard deviation (SD) of triplicate values. P values were obtained using the Student t test for independent samples. ***P<0.001. C. 
Relative expression of miR-596 in siRNA anti-uc.8+–transfected J82 cells. Data are expressed as the means ± SD of triplicate values. P 
values were obtained using the Student t test for independent samples. ***P<0.001. D. J82 cells were transfected with a PNA mimic of miR-
596 (PNA-596). Minimum free energy = -51.10 kcal/mol. Data are expressed as the means ± SD of triplicate values. P values were obtained 
using the Student t test for independent samples. ***P<0.001. E. Predicted co-folded secondary structure of uc.8+ (green sequence) bound 
to miR-596 (in red), according to the RNAfold browser. F. The blue sequence shows that PNA-596 is perfectly complementary to uc.8+.
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DISCUSSION
We identified a new long non-coding RNA transcript 
containing uc.8+, the highly ultraconserved sequence 
described by Bejerano et al. [1] uc.8+ is highly conserved 
across several species, including rats, mice, humans, 
chimpanzees (99%), dogs (99%), zebrafish (91%), and 
fugu (86%). This extremely high conservation suggests 
that these T-UCRs may play essential roles in cellular 
biology that are similar across species.
We found that the expression of uc.8+ was highly 
upregulated in BlCa tissues and cell lines and that the 
silencing of uc.8+ expression in BlCa cells, markedly 
reduced cell proliferation, migration, and invasion. 
These findings suggest that, in normal cells, uc.8+ has a 
function unrelated to tumorigenesis but that its increased 
expression after cell transformation, promotes tumor cell 
growth, migration, and invasion.
Recently, researchers demonstrated that uc.283+A 
controls pri-miR processing [17], pointing to another 
layer of regulation of miR activity; to determine whether 
T-UCRs modulate miR activity, we investigated the 
miR-binding domain accessibility, as determined by 
base-pairing interactions within the uc.8+ predicted 
secondary structure, RNA binding affinity, and RNA 
species abundance in bladder tissues. It has been reported 
that RNA conformations within a single transcript were 
a determinant of whether the transcript was targeted by 
specific miRs, as target sites buried in secondary structures 
may sterically hinder the sequence involved in the 
binding with miRs. The accessibility of miR target sites 
can change under different biological states, indicating 
an additional layer of gene regulation [18]. We found 
Figure 8: Cellular localization of ultraconserved RNA (uc). 8+. A. Images acquired using inverted fluorescence microscope 
(magnification, 20×) of J82 control cells (Mock) after transfection with PNA-TO scramble-R8 (PNA-scramble) or with TO-PNA1-R8, the 
PNA complementary to uc.8+ (PNA-uc.8+). Images were recorded with excitation wavelength (lex)=450–490 nm (DAPI) or lex=510–540 
nm (PNA-TO); the superimposition of the images recorded is also reported (Merge). All images were taken with the same confocal 
microscopy settings. Scale bar, 100 mm. Nuclei of J82 cells were stained with DAPI (blue). B. Inverse correlation between the expression 
of microRNA (miR)-596 and MMP9 in BlCa samples from 20 patients measured using qRT-PCR. C. Relative expression of MMP9 in 
siRNA-3 anti-uc.8+ –transfected J82 cells. Endogenous uc.8+ levels in the control cells are shown in grey. Data are expressed as the means 
± standard deviation of triplicate values. P values were obtained using the Student t test for independent samples. **P<0.01.
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that the binding site for miR-596 on uc.8+ is localized 
in a region that is structurally available to binding; 
furthermore, the uc.8+ binding site for miR-596 is fully 
conserved across several species’ genomes and occurs in 
a region with the highest energy score for the predicted 
co-folded secondary structure of uc.8+. Moreover, the 216 
ultraconserved nucleotides in the entire 2435-bp uc.8+ 
transcript conserved the predicted secondary structure 
of uc.8+ that instead changed with the addition of more 
artificial flanking base pairs to the real transcript sequence. 
Therefore, the interaction between miR-596 and uc.8+ 
appears to be not only bp-mediated but also structurally 
accessible.
Cellular location is an important determinant in 
understanding the functional roles of non-coding RNAs. 
Fluorescence microscopy results for J82 cells showed 
that uc.8+ and miR-596 co-existed in cytoplasm and 
were mutually available to interact, supporting the role 
of T-UCRs as regulators of gene expression through the 
modulation of miR activity. Furthermore, our in situ 
hybridization findings in BlCa tissues indicated that 
positive spots for uc.8+ occurred mainly in the nucleus 
in both NBE and high-grade BlCa, whereas in low-
grade BlCa, the spot signals were mainly delocalized 
in the cytoplasm, where uc.8+ can interact with other 
cytoplasmic molecules in the early stages of cancer. 
Additionally, the expression of uc.8+ tended to be 
inversely related to BlCa grade and stage, suggesting that 
an early alteration of uc.8+ expression is involved in BlCa 
development.
We validated the interaction between uc.8+ and miR-
596 via a fishing/competition approach with a biotinylated 
PNA probe. The identification of RNA complexes is usually 
performed via incubating cells with cross-linking fixatives 
such as formaldehyde or 4’-aminomethyl trioxsalen, 
which may impair or alter the cell environment [19, 20]. 
The highly specific PNA probe for uc.8+ allowed us to 
isolate the uc.8+::miR-596 complex in an environment 
that approximated the physiological condition. To confirm 
this interaction, we designed and produced a PNA that 
was perfectly complementary to uc.8+ in the region of the 
miR-binding site. Our results show that miR-596 interacted 
with uc.8+. We also foud an inverse correlation between 
uc.8+ and miR-596 in cancer tissues, indicating that the 
interaction between miR-596 and uc.8+ actually occurs in 
vivo. We found that uc.8+ acts as a decoy for miR-596, 
inducing the upregulation of its targets, including MMP9, 
which supports previous findings that miR-596 is a tumor 
suppressor involved in regulating MMP9 [16]. Like other 
proteases in the MMP family, MMP9 is involved in the 
degradation of collagen IV in the basement membrane 
and extracellular matrix and facilitates tumor progression, 
including invasion and metastasis. Our results help explain 
how T-UCRs control cellular events via base pairing. 
Additionally, we show that the expression of miR-596 is 
reduced by uc.8+, which acts like a sponge; this finding is 
consistent with a previous report [21]. We speculate that 
the miRNA-596 bound to uc.8+ may be partially degraded 
by a mechanism analogous to that observed for antagomirs 
that promote miRNAs degradation. However, the exact 
mechanism is still unclear, and we will focus on this topic 
in future research.
Clustered T-UCRs localized in the intronic region 
of CASZ1 are differentially expressed in cancer cells and 
are members of the BlCa signature: uc.3+, uc.4+, and 
uc.5+ expression is downregulated and uc.8+ expression 
is upregulated in BlCa tissue. In a mouse model, some 
of the scanned conserved regions in this locus, including 
uc.2+, uc.5+, and uc.8+, activate flanking genes and have 
been associated with gene regulation [22]. Given the 
decades of research focused on transcriptional control 
from a transcription factor point of view, it is interesting 
to speculate about the purpose of this additional layer of 
regulation carried out by non-coding RNAs as suggested 
by the intronic localization of the seven T-UCRs in CASZ1. 
Therefore, the discovery of uc.8+ as a sponge for miRs is 
an example of interepigenetic regulation and also indicates 
the richness of the genetic regulatory machinery. These 
interactions between evolutionarily conserved regions 
of DNA suggest that natural selection has preserved this 
potentially regulatory layer that uses RNA to modulate 
miR levels, opening up the possibility for development of 
useful markers for early diagnosis and prognosis as well 
as for development of new RNA-based cancer therapies.
MATERIALS AND METHODS
Patient samples
Five BlCa datasets were used for this study (Table 
1). Dataset 1 included samples from 24 patients and 
17 NBE samples. Dataset 2 included PBlCa and BlCa 
samples from three patients. Each of the BlCa samples 
was hybridized in triplicate, but the surrounding tissues 
were hybridized once owing to the limited available 
tissue. Dataset 3 included PBlCa and BlCa samples from 
18 patients. Dataset 4 included BlCa samples from 40 
patients and 16 NBE samples. Dataset 5 included BlCa 
samples from 18 patients. The control group consisted of 
NBE tissue samples obtained from men who underwent 
retropubic prostatic adenomectomy for benign prostatic 
hyperplasia. Tumor samples from datasets 1 and 2 were 
used to determine ultraconserved genome expression 
profiles, whereas tumor samples from dataset 3 and 4 
were used as validation set. Dataset 5 samples were used 
for in situ hybridization. Subgroups of patients were 
chosen from the datasets 3 and 4 randomly as independent 
validation sets. All patients were classified according to 
the 1997 UICC TNM classification for the stage and OMS 
2004 for the grade. Table 1  lists the clinical characteristics 
of the BlCa patients. The demographic data of the groups 
did not differ. Patients with low-grade BlCa underwent 
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transurethral resection, and those with high-grade 
BlCa received radical cystectomy. None of the patients 
underwent preoperative radiotherapy, chemotherapy, or 
other cancer treatments. The participants provided written 
informed consent.
All of the tissue samples were collected at a major 
urological center (University “Federico II,” Naples, Italy) 
from 2008 to 2012, and the histological samples were 
obtained from the Pathology Unit and at the National 
Cancer Institute-IRCCS “G.Pascale Foundation. All 
tumor samples used in this study contained more than 80% 
tumor cells. Each sample was evaluated by a pathologist 
to confirm the postoperative pathologic diagnosis, which 
was performed by all of the tumor samples used in this 
study. All postoperative pathological diagnosis were done 
by two independent pathologists. All samples were stored 
in liquid nitrogen immediately after resection and were 
transferred to a -80°C freezer.
Cell lines
Human BlCa cell lines J82 (ATCC) and RT112 
(European Collection of Cell Cultures) were cultured 
as a monolayer in Minimal Essential Medium and 
Roswell Park Memorial Institute medium, respectively, 
supplemented with 10% fetal bovine serum. All cells 
grew in a humidified incubator in a 5% carbon dioxide 
atmosphere at 37°C.
T-UCR expression profiling
RNA was extracted from tissue samples by using 
TRIzol reagent (Thermo Fisher Scientific). Total RNA 
(5 μg) was reverse-transcribed with biotin-end-labeled 
random oligonucleotide primers, and cDNA was 
hybridized to a custom microarray (OSU-CCC 4.0, Ohio 
State University Comprehensive Cancer Center), which 
included sense and antisense probes, one corresponding 
to the sense genomic sequence (named “+”) and the 
other to the complementary sequence (named “+A”) for 
all 481 human ultraconserved sequences reported by 
Bejerano et al [1]. Each probe was spotted in duplicate in 
two different slide locations, and therefore quadruplicate 
numerical values were available for analysis [2, 23]. 
Biotin-containing transcripts of all T-UCRs were detected 
in BlCa using an AlexaFluor 647 streptavidin conjugate 
(Thermo Fisher Scientific). Samples were scanned and 
analyzed using an Axon GenePix 4000B microarray 
scanner and GenePix software, version 6.0 (Axon 
Instruments). The mean fluorescence intensity of replicate 
spots of each probe on the microarray was subtracted 
from the background and was normalized using the global 
median method. T-UCRs present in all three replicates 
of each sample were selected for analysis. Differentially 
expressed T-UCRs were identified using class comparison 
analysis with BRB-ArrayTools software (version 3.6.0; 
Biometric Research Program, National Cancer Institute) 
[24]. The criterion for including a gene in the gene list 
was a P value less than 0.05. Normalized and raw T-UCR 
data files were uploaded to the Gene Expression Omnibus 
under accession number GSE68594.
Reannotation of T-UCRs
All T-UCRs were reannotated using the current 
version of the reference genome (GRCh38/hg38), and 
their relationship with genomic annotations (ENCODE, 
Stanford University; GENCODE, Wellcome Trust Sanger 
Institute) was established.
RNA extraction, reverse transcription, and  
qRT-PCR
Total RNA was extracted from BlCa and NBE 
samples and J82 and RT112 cells using TRIzol 
reagent. The concentration of RNA was determined by 
260/280 nm absorbance using a NanoDrop ND-1000 
spectrophotometer (Thermo Scientific), and the integrity 
of RNA was checked using gel electrophoresis. Total RNA 
(1 μg) was reverse-transcribed using an iScript Select 
cDNA Synthesis kit (Bio-Rad). qRT-PCR was performed 
using strand-specific primers for UCR analysis and 
random primers for CASZ1 expression (Supplementary 
Table S5). A miRCURY LNA Universal RT miR PCR 
kit (Exiqon) was used for miR analysis according to 
the manufacturer’s instructions. RT-PCR analysis was 
performed using an iQ SYBR Green Supermix (Bio-
Rad) protocol with a CFX96Deep Well system Real-
Time PCR Detection System (Bio-Rad) according to the 
manufacturer’s instructions. Small nuclear RNA U6 was 
used as a reference for T-UCRs and miRs. Supplementary 
Table S5 lists primers used in this study for qRT-PCR. 
Each BlCa sample was analyzed in triplicate. The 2-
ΔΔct method was used for relative quantitation of gene 
expression, and results are expressed as log10 (2-ΔΔct).
In situ RNA hybridization on paraffin sections
uc.8+ RNA antisense probe was synthesized 
from linearized plasmid in presence of digoxigenin-11-
UTP (Roche). Tissue sections were dewaxed in xylene, 
rehydrated, postfixed in 4% paraformaldehyde, digested 
with proteinase K (10 μg/mL) for 10 min, subjected to 
acetylation for 15 min, prehybridized for 1 h, and then 
hybridized at 65°C overnight in 50% formamide; 0.25% 
sodium dodecyl sulfate; 10% dextran sulfate; 1× Denhardt 
solution; Tris HCl (pH 7.5, 10 mM); NaCl (600 mM); 
EDTA (1 mM); transfer RNA (200 mg/mL); and salmon 
sperm DNA (100 mg/mL), using a probe concentration of 
0.8–1 mg/mL. Tissue sections were washed in 1× saline 
sodium citrate buffer (50% formamide) at 65°C for 30 min 
and then in 2× saline sodium citrate buffer for 20 min and 
in 0.2× saline sodium citrate buffer twice for 20 min each. 
After the washes, tissue sections were incubated overnight 
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at 4°C with alkaline-phosphatase-coupled anti-digoxigenin 
antibodies (1:2000; Roche). After seven washes in maleic 
acid buffer containing Tween 20 for 1 h each and three 
washes in NTMT solution for 10 min each, tissue sections 
were incubated with nitro blue tetrazolium chloride and 
5-bromo-4-chloro-3-indolyl-phosphate, 4-toluidine salt 
solution (Roche) and developed a blue color. Tissue 
sections were then mounted directly or after eosin staining. 
Stained sections were examined and photographed using a 
Leica MZ12 dissection microscope and a Nikon ECLIPSE 
Ni microscope. All the images were processed in Adobe 
Photoshop, version 10.0 (Adobe System Inc.).
uc.8+ siRNA transfection of BlCa cells
J82 and RT112 cells were transfected with siRNAs 
using HiPerFect transfection reagent (QIAGEN). siRNAs 
were designed using siDirect software [25] with input of 
the complete uc.8+ sequence. uc.8+ gene silencing in J82 
cells was studied to exclude the possibility of an off-target 
effect of siRNA anti-uc.8+. According to the scores of 16 
siRNA candidates in the siDirect design site, we selected 
three sequences designated as siRNA-1, siRNA-2, and 
siRNA-3 (Supplementary Table S5) on the basis of their 
reduced capability to induce off-target effects correlated 
with the thermodynamic stability of the seed-target duplex 
(<10°C for siRNA-1 and siRNA-3 and <15° for siRNA-2).
All oligomers were synthesized using an ABI 
Expedite 8909 oligosynthesizer with standard protocols (1-
μM scale), 5′-O-DMT-2′-O-TBDMS-RNA phosphoramidite 
monomers, and standard RNA synthesis reagents (Link 
Technologies) with Universal SynBase CPG 1000/110 solid 
support (CPG-OH, loading 0.04 meq g-1). High-performance 
liquid chromatographic analyses and purification of siRNAs 
were performed with NUCLEOGEL SAX (MACHEREY-
NAGEL; 1000-8/46, eluted with a gradient from 0% to 
100% B in A in 30 min, flow rate of 1 mL/min, λ = 260 nm; 
A: KH2PO4 [pH 7.0, 20 mM] and 20% [v/v] acetonitrile; 
B: KCl [1 M], KH2PO4 [pH 7.0, 20 mM], and 20% [v/v] 
acetonitrile) and RP-18 columns (Waters; C-18, 3.9 × 
300 mm, eluted with solvent A [ammonium acetate (pH 
7, 100 mM)] and solvent B [5%-60% acetonitrile] for 
40 min, flow rate of 1.0 mL/min, λ = 260 nm) using a 
Waters 600 HPLC controller equipped with a Waters 996 
photodiode array detector and Millennium software. The 
concentration of siRNA oligonucleotideswas estimated 
spectrophotometrically at 90°C using the following additive 
molar extinction coefficients: ε260 (L cm-1 mol-1) T=8800, 
A=15400, C=7200, G=11500, and U=9900 for the natural 
nucleobases.
RNA oligomers were analyzed using matrix-
assisted laser desorption/ionization time-of-flight mass 
spectrometry ( expressed in Da): 1 guide, mass calculated 
7322, mass found 7331; 1 passenger, mass calculated 
7204, mass found 7212; 2 guide, mass calculated 7081, 
mass found 7086; 2 passenger, mass calculated 7416, mass 
found 7418; 3 guide, mass calculated 7268, mass found 
7275; and 3 passenger, mass calculated 7234, mass found 
7244. Cells were transfected with siRNAs anti-uc.8+ or a 
nontargeting siRNA control at a concentration of 100 nM. 
Cells were collected 48 h after transfection.
Transfection of mimic miR-596
J82 and RT112 cells (200,000 cells/well) were 
plated in six-well plates and incubated for about 3 h at 
37°C. After incubation, cells were transfected with mimic 
miR-596 (QIAGEN) and AllStars Negative Control 
siRNA (QIAGEN) using HiPerFect transfection reagent 
at a final concentration of 5 nM. Cells were harvested 48 
h after transfection and were subjected to RNA extraction. 
Reverse-transcriptase PCR and qRT-PCR analysis of miR-
596 were conducted as described previously.
RACE
To identify the 5′ and 3′ ends of the uc.8+ transcript, 
total RNA from J82 cells was extracted and treated with 
DNase I (RNase-free) endonuclease (Thermo Fisher 
Scientific), and the SMARTer RACE cDNA Amplification 
kit (Clontech) was used to generate RACE-ready cDNA 
according to the manufacturer’s instructions. The cDNA 
ends were amplified with Platinum Taq DNA Polymerase 
High Fidelity (Thermo Fisher Scientific), and gene-specific 
primers (GSP1: 5′-AGAGAGAGATGACTTTCCTTG-3′; 
GSP2: 5′-TCCTGAGTTTAAAGCCACAGTG -3′) were 
used. The primer for the 5′ end was designed to keep 
it from overlapping with the transcript of the CASZ1 
host gene, ensuring that only the uc.8+ transcript was 
amplified. Furthermore, nested PCR analysis was 
performed with the nested universal primer provided 
with the kit (SMARTer RACE cDNA Amplification kit) 
and two nested gene-specific primers (NESTED-GSP1: 
5′- GGTCGCCATGGATATGACA -3′; NESTED-GSP2: 
5′-GGGGAAAGATACAAGGAGAA-3′). Placental RNA 
and transferrin receptor-specific primers provided with the 
kit were used as reaction controls.
The PCR fragments were then run on a 1.5% 
agarose gel, and DNA was extracted from the gel using 
a QIAquick Gel Extraction kit (QIAGEN) according to 
the manufacturer’s instructions. The RACE products 
were then cloned into a TOPO TA pCR2.1 cloning vector 
(Thermo Fisher Scientific) according to the manufacturer’s 
instructions, sequenced using the T7 and T3 primers and 
aligned using the UCSC Genome Browser (University of 
California Santa Cruz). DNA marker, 1-kb DNA ladder 
(Promega; catalog no. G571).
Cell proliferation assays
Following uc.8+ silencing with siRNAs-2 and -3, 
BlCa cell proliferation was measured using the CellTiter 
96 nonradioactive proliferation assay (Promega). J82 
cells were seeded (500 cells per well) in 96-well plates 
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and assayed 0, 12, and 24 h later according to the 
manufacturer’s protocol.
Cell cycle assays
J82 cells were harvested 72 h before treatment with 
siRNA control or siRNA-3 anti-uc.8+, fixed in 70% ethanol 
and stained in a solution containing 20 μg/ml of propidium 
iodide (Sigma Aldrich), 200 μg/ml (0.08 KU) of RNase 
(Serva). After 60 min, samples were analyzed by flow 
cytometry using a BD FACSCantoIITM cytofluorimeter 
(BD Biosciences). Data acquisition (10,000 events were 
collected for each sample) was performed by using the 
BD FACSDivaTM software (BD Biosciences), according 
to the manufacturer’s instructions. Data were elaborated 
using the same software (BD FACSDivaTM software), 
according to the manufacturer’s instructions and expressed 
as fractions of cells in the different cycle phases.
In vitro wound-healing (migration) assay
A wound-healing assay was performed in siRNA-3 
anti-uc.8+–transfected and untransfected cells to study 
cell migration with J82 cells (200,000 per well) seeded 
in six-well plates and incubated for about 3 h at 37°C, 
allowing the cells to adhere to and spread on the substrate 
completely. A single scratch was made in the urothelial 
monolayer using a micropipette tip. Subsequently, cells 
were washed once with phosphate-buffered saline solution 
and then were incubated. During the assay, cells were 
viewed under a Leica phase-contrast microscope with a 
10× objective, and photographs of fixed positions on the 
wounds were taken after 0, 12, 24, and 36 h. The wound 
width was calculated by measuring the mean distance 
between the margins of the wound in randomly selected 
fields on the photographs. Cell migration was quantified 
by calculating the area of the wound at time points t0 
(time of wounding), t24 (24 h after wounding), and t36 
(36 h after wounding) by using the following formula: area 
(t0) - area (t24 or t36)/area (t0). Multiple photographs of 
the same spots in the wound area were then taken 12, 24, 
and 36 h after siRNA transfection for comparison. Four 
independent wound-healing assays were performed.
Matrigel invasion assay
The invasiveness of J82 cells following uc.8+ 
silencing was determined using Boyden transwell assays. 
Polycarbonate filters with 8.0-μm pores (BD Biosciences) 
were coated with matrigel (40 μL) and were incubated in a 
humidified incubator at 37°C to allow for polymerization. 
The lower compartment of each chamber was filled with 
minimum essential medium supplemented with 10% fetal 
bovine serum. J82 cell groups and mock, scrambled, and 
siRNAs anti-uc.8+ were placed in serum-free minimum 
essential medium (0.2 mL) and were seeded on top of the 
collagen in the upper compartment of each chamber (4 
× 104 cells/chamber). After incubating at 37°C for 24 h, 
the cells on the upper surface of the filter were removed 
by wiping. Cells that traversed the filter were fixed with 
ice-cold methanol (1 mL) and were incubated for 10 min 
at room temperature. The methanol was aspired, and cells 
were stained with 1% crystal violet in 2% ethanol for 1 h 
in the dark. Excess crystal violet was removed by quickly 
merging the insert of the chamber in double-distilled water 
for 3–4 s several times. Excess water was drained from 
the side of the insert using a cotton swab, and the insert 
membrane was dried. We counted the cells on the lower 
side of the filter under a microscope (magnification 20x) 
by randomly choosing different views and calculating 
averages (five points for each transwell). Each migration 
condition was repeated in triplicate.
Identification of miR-binding sites in 
ultraconserved RNA sequences
The T-UCR sequences described in the supplementary 
data reported by Bejerano et al [1] were converted to 
reverse-complementary RNA using Common Application 
Program Remote Interface software CAPRI, available at the 
bioinformatics portal of the CEINGE website. Human miR 
sequences with high confidence, i.e., those with a highly 
conserved level of identity throughout various mammalian 
species, were selected from the online database miRBase 
(release 19, University of Manchester) [26–30]. The 
target prediction tool RNAhybrid (version 2.1, Bielefeld 
University) was used to identify putative miR target sites 
in T-UCR sequences [13]. T-UCR::miR duplex formation 
was evaluated under highly stringent conditions using 
constraint-of-seed nucleotide matching of nucleotides 2–7 
[31, 32] and a P value less than 0.05. The analysis focused 
on the 293 T-UCRs identified in microarray profiling of 
tissue samples obtained from BlCa patients.
Prediction of the uc.8+ secondary structure
We used 216 ultraconserved nucleotides and the 
whole 2435-bp transcript of the uc.8+ sequence to predict 
the folding of the uc.8+ secondary structure with RNAfold 
software (Vienna RNA Package) [32]. Prediction of the 
folding of the secondary structure of the uc.8+::miR-596 
duplex was carried out using RNAcofold software (version 
2.1.5, Vienna RNA Package) [33].
Magnetic labeling and isolation of biotinylated 
molecules (uc.8+ fishing in J82 cells)
Total RNA (300 μg) extracted from J82 cells was 
added to an appropriate buffer with 5′-biotinylated PNA 
oligomer uc.8+ (100 pmol) and was incubated overnight 
at 4°C with rotation. After complex formation, μMACS 
Streptavidin MicroBeads (100 μL, Miltenyi Biotec) were 
added to the mixture and incubated for 30 min at 4°C. 
μMACS columns were equilibrated with equilibration 
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buffer for nucleic acids (100 μL) and were rinsed with 
the same buffer used for the binding reaction. Labeled 
complexes were applied to the top of the column matrix. 
Columns were washed with washing buffer (4 × 100 μL) 
to remove molecules with nonspecific binding. RNA 
labeled with biotinylated PNA oligomer was eluted with 
elution buffer (150 μL, μMACS Streptavidin kit 130-074-
101, Miltenyi Biotec) according to the manufacturer’s 
instructions. We used a 5′-biotinylated scrambled 
oligonucleotide as a control.
PNA synthesis
HATU was purchased from InBios. Fmoc-PNA-
cytosine(Bhoc)-OH, Fmoc-PNA-thymine-OH, Fmoc-
PNA-guanine(Bhoc)-OH, and Fmoc-PNA-adenine(Bhoc)-
OH were obtained from Link Technologies. Acetonitrile 
for liquid chromatography–mass spectrometry, N,N-
dimethylformamide (DMF) for solid-phase synthesis, N,N-
diisopropylethylamine (DIPEA), and dichloromethane 
were obtained from ROMIL. N-methylmorpholine and 
piperidine were obtained from Fluka and Biosolve, 
respectively. Fmoc-PAL-PEG-PS resin (0.18 mmol/g) was 
obtained from Applied Biosystems. All other chemicals 
were supplied by Sigma-Aldrich and were used without 
further purification.
Preparative purification of PNA oligomers was 
carried out using a Shimadzu LC-8A solvent delivery pump 
equipped with an SPD-M10AVP diode array detector. 
Preparative high-performance liquid chromatography was 
performed using a Phenomenex Jupiter 10-μm Proteo 
column (90 Ǻ, 250 × 10 mm) with a linear gradient of 
acetonitrile (0.1% trifluoroacetic acid) from 5% to 50% in 
water (0.1% trifluoroacetic acid) for 30 min with a flow 
rate of 5 mL/min-1. Pure products were characterized using 
liquid chromatography–mass spectrometry with an Agilent 
PL1110-6320 time-of-flight system.
Biotinylated PNAs
PNA syntheses were carried out on a 2-μmol scale, 
following standard procedures [34, 35]. At the end of 
the synthesis, after deprotection of the N-terminal amine 
with a solution of a 20% piperidine in DMF, the PNA was 
subjected to derivatization with biotin. Five equivalents 
of N-biotinyl-aminohexanoic acid were dissolved in a 
solution of HATU (4.9 eq) in DMF (0.5 M) and DIPEA 
(7 eq) and reacted for 1 h. The reaction was performed 
twice to improve the coupling efficiency. Cleavage of the 
oligomers from the resin and deprotection were carried out 
as reported elsewhere [35].
Fluorescent PNAs
Solid-phase synthesis of TO-PNA1-R8 was 
performed. The peptide (R8) was assembled following 
previously described procedures [15]. Next the PNA 
oligomer was assembled, as described above. We 
conjugated the fluorescent dye TO following previously 
described procedures [36, 37]. All PNA oligomers were 
purified and then characterized by liquid chromatography–
mass spectrometry using a linear gradient of acetonitrile 
(0.05% trifluoroacetic acid) in water (0.05% trifluoroacetic 
acid) from 5% to 50% over 30 min. The sequences of PNA 
oligomers and mass spectrometry data of all the PNA used 
for this study are reported in Supplementry Table S6.
PNA-596 and PNA-anti-uc.8+ transfections
J82 cells (150,000 cells per well) were seeded in 
6-well plates and were incubated for approximately 1 h at 
37°C. After incubation, cells were transfected with PNA-
596 and PNA TO-PNA1-R8 using HiPerFect Transfection 
Reagent, at a final concentration of 200 nM for PNA-596 
and 4 μM for TO-PNA1-R8. The transfected J82 cells were 
harvested after 48 h. The experiments were conducted in 
technician triplicate and in biological replicate.
Statistical analysis
All statistical analyses were performed using the R 
programming language (version 3.0.1). Each experiment 
was done at least twice, and at least one of the two sets 
of experiments was done in triplicate. The differences in 
T-UCR expression between tumor and non-tumor tissue 
were compared pairwise using Significant Analysis of 
Microarray software (Stanford University). Comparisons 
between independent samples were performed using either 
the Student t test or the nonparametric Mann-Whitney 
U test with Bonferroni correction when appropriate, as 
appropriate. Comparison between dependent samples was 
performed using the nonparametric Wilcoxon signed-rank 
test for matched pairs. Unless otherwise specified, data 
are summarized and graphically represented as means ± 
SDs. Correlations were computed using the Spearman 
correlation coefficient. Two-sided P values less than 0.05 
were considered statistically significant.
Data and material availability
J82 cells are commercially available from the 
American Type Culture Collection (catalog number HTB-
1), and RT112 cells are available from the European 
Collection of Cell Cultures (catalog number 85061106).
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